CONTEXT AND OBJECTIVE: The presence of a certain degree of inflammation in the gut wall is now accepted in irritable bowel syndrome (IBS). Fecal calprotectin is considered to be a reliable test for detecting intestinal inflammation. Our aim was to assess the presence of inflammation in postinfectious IBS (PI-IBS), compared with non-postinfectious IBS (NPI-IBS). A secondary objective was to determine the usefulness of a rapid fecal calprotectin test in inflammatory bowel diseases (IBD 
INTRODUCTION
It is now accepted that a certain degree of inflammation in the gut wall is present in irritable bowel syndrome. 1 Since irritable bowel syndrome is a functional disorder, with a very good prognosis in terms of survival, it is preferable to use noninvasive tests in order to evaluate the presence of inflammation. More than a decade ago, measurement of calprotectin in feces was proposed as a surrogate marker of intestinal inflammation. 2 Calprotectin represents 60% of granulocytic cytosolic proteins, and therefore its concentration reflects the neutrophil migration in the gastrointestinal tract. Increased levels of calprotectin indicate intestinal inflammation, but it is not disease-specific. 3 Over the last few years, several studies have focused on evaluating the value of fecal calprotectin for detecting mucosal inflammation, especially in patients with inflammatory bowel disease, both in an active phase and in clinical remission.
Patients with clinically quiescent inflammatory bowel disease have some degree of mucosal inflammation, 4 as proved by high levels of fecal calprotectin. For example, Sipponen et al. reported that there were high levels of calprotectin (up to 1000 mcg/g) in 13% of their inflammatory bowel disease patients who were in clinical remission. 5 Fecal calprotectin also has prognostic value, such that the probability of remaining in clinical remission is higher when the fecal calprotectin level is low. 5 There is also evidence that patients with mucosal healing seen through endoscopy have lower or normal fecal calprotectin levels. 6, 7 Fecal calprotectin levels also become increased in other organic disorders such as small bowel enteropathy, microscopic colitis, infectious diarrhea, segmental colitis associated with diverticulosis and colorectal cancer. 8 Fecal calprotectin levels are low both in irritable bowel syndrome patients and in healthy controls. 8, 9 Several studies have shown that increased fecal calprotectin levels can differentiate between organic colonic diseases and nonorganic disease (especially irritable bowel syndrome), in symptomatic patients. 8, 10 Using a cutoff of 10 mg/l, fecal calprotectin had sensitivity of 89% and specificity of 79% for organic disease. 8 Postinfectious irritable bowel syndrome is a specific type of irritable bowel syndrome, acknowledged by the Rome working committees. 1 However, there is evidence that postinfectious irri- We started from the hypothesis that fecal calprotectin would be positive in a higher proportion of patients with postinfectious irritable bowel syndrome, compared with non-postinfectious irritable bowel syndrome patients.
OBJECTIVE
The main objective of our study was to find out whether there were any differences in fecal calprotectin levels in patients with postinfectious irritable bowel syndrome, compared with non-postinfectious irritable bowel syndrome patients, using a rapid semiquantitative fecal calprotectin test. A second objective of the study was to investigate the usefulness of a rapid and inexpensive fecal calprotectin test in a group of patients with obvious intestinal inflammation, such as patients with inflammatory bowel diseases.
METHODS

Study design and setting
This was a cross-sectional study carried out in a public hospital for six months in 2012.
Subjects
Irritable bowel syndrome patients
A total of 116 consecutive irritable bowel syndrome patients referred to a single tertiary gastroenterology department were prospectively included in this study after they gave their informed consent. The patients were diagnosed as having irri- were female. There were no differences regarding age and gender between the postinfectious irritable bowel syndrome group and the non-postinfectious irritable bowel syndrome group.
Patients with coexisting cardiovascular, pulmonary, hepatic, renal or musculoskeletal disease, severe immune defi ciency, malignancy or alcohol abuse, or who were receiving non-steroidal anti-infl ammatory drugs, were excluded from the study because these conditions may be associated with intestinal infl ammation. 13, 14 Patients with menstrual or nasal bleeding during the fi ve days prior to fecal testing were also excluded, since blood in the feces could increase the calprotectin levels.
15,16
Infl ammatory bowel disease patients
Fecal calprotectin levels are high in patients with infl ammatory bowel diseases, 5 and vary with the severity of infl ammation.
Fecal calprotectin is used in current practice to monitor the evolution of patients with infl ammatory bowel diseases, but the costs of ELISA (enzyme-linked immunosorbent assay) tests are quite high. In order to achieve the second objective of this study and to confi rm previously published data, 3, 5 we applied a rapid and inexpensive fecal calprotectin test to a small group of patients with infl ammatory bowel diseases.
We selected Crohn's disease complications (fi stulae, abscesses or symptomatic intestinal strictures requiring surgery) were excluded.
Assessment of fecal calprotectin
We assessed intestinal infl ammation by means of a rapid, semi- 2 ).
All patients, both those with irritable bowel syndrome and those with infl ammatory bowel disease, were evaluated using this fecal calprotectin test, but no comparison between the two groups was made.
Statistical analysis
Descriptive statistics (mean ± standard deviation) were used for for proportions. An error probability of P < 0.05 was considered statistically significant.
Ethical issues
This study was conducted in accordance with the Declaration of Helsinki regarding human studies. All patients gave their informed consent and the study received approval from our institution's Ethics Committee.
RESULTS
Fecal calprotectin in irritable bowel syndrome patients
Eight patients ( from 13% to 31%. 12, 20 In our irritable bowel syndrome group, 14.6% of the patients had a positive fecal calprotectin test (T1 positive), thus suggesting mild inflammation. Half of them had postinfectious irritable bowel syndrome. Another study that used this semiquantitative method among irritable bowel syndrome patients reported that there was no increase in fecal calprotectin levels in irritable bowel syndrome in relation to healthy controls. 21 Our study showed that a higher proportion of patients with postinfectious irritable bowel syndrome had a positive calprotectin test, compared with patients with non-postinfectious irritable bowel syndrome. This suggests that after an acute episode of enterocolitis, there is a degree of persistent inflammation.
DISCUSSION
Other studies have also reported mild inflammation in cases of irritable bowel syndrome. Tibble et al. evaluated fecal calprotectin (using the ELISA method for quantification) in 602 patients with gastrointestinal complaints, of whom 339 were classified as presenting nonorganic disease (all of them had irritable bowel syndrome symptoms), and 263 as presenting organic disease. Fecal calprotectin < 10 mg/l was considered normal. In the nonorganic group, the median fecal calprotectin level was 4 mg/l, with a range of 1-50 mg/l. 8 Thus, several irritable bowel syndrome patients had fecal calprotectin > 10 mg/l, but < 50 mg/l, which suggested that there was some degree of inflammation in these irritable bowel syndrome cases. These authors did not provide further information regarding the postinfectious status of these patients. 8 Similar results were reported in another study. The range of fecal calprotectin detected using ELISA was 0-24 mcg/g, with a median value of 6 mcg/g. The highest sensitivity and specificity of fecal calprotectin for differentiating organic from functional disorders was observed using a cutoff value of 24.3 mcg⁄g. 22 In our study, we used a semiquantitative test to detect fecal calprotectin, with positive tests expressed in mcg/g. Thus, we cannot directly compare our results with those obtained using the ELISA method (values expressed in mg/l). However, we can say that, in the same way as shown in Tibble et al. study, 8 fecal calprotectin was positive in some of our irritable bowel syndrome patients, although only low levels were detected.
Both in the postinfectious irritable bowel syndrome and in the non-postinfectious irritable bowel syndrome, there is evidence of some degree of inflammation. Some studies have reported increased numbers of intraepithelial T lymphocytes and enterochromaffin cells in rectal biopsy specimens, 12 weeks after acute gastroenteritis, compared with the cell counts in control subjects. [23] [24] [25] In another study, the number of enterochromaffin cells was significantly higher in a group with postinfectious irritable bowel syndrome than in a group with non-postinfectious irritable bowel syndrome, but the number of T lymphocytes was similar. 26 Our study showed that a higher proportion of patients with postinfectious irritable bowel syndrome had a positive calprotectin test, compared with patients with non-postinfectious irritable bowel syndrome (33% versus 10%). This suggests that the degree of intestinal inflammation is higher in patients with postinfectious irritable bowel syndrome than in those with non-postinfectious irritable bowel syndrome.
The usefulness of fecal calprotectin testing in cases of inflammatory bowel disease has already been proven. We also tested this semiquantitative method on inflammatory bowel disease patients. Out of 20 patients with inflammatory bowel disease, 80% had a T3 positive test, i.e. fecal calprotectin > 60 mcg/g. Using ELISA testing on fecal calprotectin, a high cutoff value set at 100 mcg/g had better accuracy than the usual cutoff limit of 50 mcg/g. 27 Our cutoff value for moderate to severe inflammation (as seen in inflammatory bowel disease) was 60 mcg/g.
Only 20% of our inflammatory bowel disease patients had fecal calprotectin < 60 mcg/g. Our results from inflammatory bowel disease patients were similar to those reported in other studies, in which the calprotectin levels were rarely below 60 mcg/g, and varied widely between 54 and 6032 mcg/g. 28 A large study (including 823 patients) that used CalDetect, reported that only 7% of patients with active Crohn's disease had a calprotectin level < 15 ng/ml, while among patients with inactive Crohn's disease, 89% had a calprotectin level < 15 ng/ml. These results were very close to those observed using ELISA methods, thus resulting in very good performance for this rapid test. On the other hand, fecal calprotectin testing has some disadvantages. False positive results may occur. Thus, use of nonsteroidal anti-inflammatory drugs can increase fecal calprotectin levels. 29, 30 Age is also thought to influence calprotectin levels. 15 The presence of blood in stools (at least 100 ml/day) increases fecal calprotectin levels, and therefore testing should be avoided in patients with menstrual or nasal bleeding. 15, 16 
